🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06890533
Active, not recruiting Phase 3

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

NCT06890533 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Started
2025-05-14
Last updated
2026-06-29

Condition(s) studied

Pain

Investigational drug(s) / intervention(s)

Experimental: YZJ-4729Placebo Comparator: SalineActive Comparator: Morphine

Experimental: YZJ-4729: Loading dose + demand dose

Placebo Comparator: Saline: Loading dose + demand dose

Active Comparator: Morphine: Loading dose + demand dose

Study summary

The primary objective is to evaluate the analgesic efficacy and safety of IV YZJ-4729 Tartrate Injection in patients with acute postoperative pain following abdominal surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2. 3. ASA I - II 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery Exclusion Criteria: 1. Allergy to opioids and other medications that may be used during the trial. 2. Nervous system disorders (e.g. epilepsy) 3. Psychiatric disorders (e.g. depression) 4. History of difficult airways 5. Random blood glucose ≥11.1 mmol/L 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg),or hypotension(systolic blood pressure \<90 mmHg)\] 7. Abnormal pulse oxygen saturation (SpO2 \<90 %) 8. Abnormal liver function or renal function 9. Used agents that could affect the analgesic response 10. Used agents that could affect drug metabolism 11. Has previously participated in another YZJ-4729 clinical study

Primary outcome measure(s)

Trial sites (49)

FacilityCityRegionStatus
Cangzhou Central Hospital Cangzhou China
Cangzhou People's Hospital Cangzhou China
Changde First People's Hospital Changde China
Changsha Hospital Affiliated to Hunan University Changsha China
The Fourth Hospital OF Changsha Changsha China
The Third Xiangya Hospital of Central South University Changsha China
Sichuan Provincial People's Hospital Chengdu China
The Second People's Hospital of Chengdu Chengdu China
The Third People's Hospital of Chengdu Chengdu China
The First Affiliated Hospital of Chongqing Medical University Chongqing China
The Second Affiliated Hospital of Chongqing Medical University Chongqing China
The First Hospital of Jilin University Ch’ang-ch’un China
Affiliated Zhongshan Hospital of Dalian University Dalian China
Deyang People's Hospital Deyang China
Dongguan People's Hospital Dongguan China
Ganzhou People's Hospital Ganzhou China
The First People's Hospital of Guangyuan Guangyuan China
Guangdong Province Traditional Chinese Medical Hospital Guangzhou China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou China
The First Affiliated Hospital of Jinan University Guangzhou China
Haikou People's Hospital Haikou China
The Fourth Affiliated Hospital of Harbin Medical University Ha’erbin China
The Second People's Hospital of Hefei Hefei China
The First Affiliated Hospital of University of South China Hengyang China
Huzhou Central Hospital Huzhou China
The First Hospital of Jiaxing Jiaxing China
Liuzhou People's Hospital Liuzhou China
Liuzhou Workers' Hospital Liuzhou China
Luoyang Central Hospital Luoyang China
Ma'anshan People's Hospital Ma’anshan China
Mianyang Central Hospital Mianyang China
JiangXi Provincial People's Hospital Nanchang China
The Second Nanning People's Hospital Nanning China
The Second People's Hospital of Neijiang Neijiang China
Ningbo Medical Center Lihuili Hospital Ningbo China
Qingdao Central Hospital of Rehabilitation University Qingdao China
Shanghai First Maternity and Infant Hospital Shanghai China
Shanghai Fourth People's Hospital Shanghai China
Taizhou People's Hospital Taizhou China
The Second Hospital of Tianjin Medical University Tianjin China

+ 9 more sites — see the full list on the official registry below.

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06890533 on ClinicalTrials.gov ↗ ← All trials in China